The 58th Annual ASH meeting & exposition was held was held December 3-6, 2016 in San Diego, CA. The following are the 8 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.  Click on the poster to download a full size PDF version.

Lian Xu, Steven Treon, Jorge Castillo

Jiaji (George) Chen, Xia Liu, Guang Yang, Josh Gustine

Lower doses of bendamustine are not associated with worse response depth in patients with Waldenström macroglobulinemia

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Irene M. Ghobrial, and Steven P. Treon

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells that is Accompanied by ERK1/2 Hyperactivation, and is Targeted by the Addition of the ERK1/2 Inhibitor Ulixertinib

Chen JG, Liu X, Chen J, Xu L, Tsakmaklis N, Demos M, Patterson CJ, Castillo JJ, Hunter ZR, Treon SP, Yang G.

 HCK Transcription is Regulated by AP1, NF-kB and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Liu X, Chen JG, Chen J, Xu L, Tsakmaklis N, Demos M, Patterson CJ, Castillo JJ, Hunter ZR, Treon SP, Yang G.

The high risk of symptomatic hyperviscosity in patients with high serum IgM levels can be used to support initiation of treatment in Waldenström macroglobulinemia

Joshua N. Gustine, Kirsten Meid, Robert Manning, Toni Dubeau, Irene M. Ghobrial, Steven P. Treon, and Jorge J. Castillo

Ixazomib, dexamethasone and rituximab (IDR) as primary therapy for symptomatic Waldenström macroglobulinemia

Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Toni Dubeau, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

Jorge J. Castillo, MD, Artur J. Jurczyszyn, MD, PhD, Edvan Crusoe, MD, MsC, Jacek Czepiel, MD, Julio Davila, MD, Angela Dispenzieri, MD, Marion Eveillard, PharmD, PhD, Mark A Fiala, BS, CCRP, Irene M. Ghobrial, MD, Alessandro Gozzetti, MD, Joshua Gustine, MPH, Roman Hájek, MD PhD, Vânia Hungria, MD, Jiri Jarkovsky, MSc, PhD, David Jayabalan, BSMS, MSc, Jacob P Laubach, MD, Barbara Lewicka, MD, Vladimir Maisnar, MD, PhD, Elisabeth E. Manasanch, MD, Philippe Moreau, MD, Hareth Nahi, MD, Ruben Niesvizky, MD, Claudia E. Paba-Prada, MD, Tomas Pika, MD, PhD, Ludek Pour, MD, PhD, John L Reagan, MD, Paul G Richardson, MD, Jatin J. Shah, MD, Ivan Spicka, MD PhD, Ravi Vij, MD, Anna Waszczuk, MD, PhD and Morie A Gertz, MD; MACP

Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom’s Macroglobulinemia

Treon SP, Tsakmaklis N, Meid K, Yang G, Chen JG, Liu X, Chen J, Demos M, Patterson CJ, Dubeau T, Gustine J, Castillo JJ, Advani R, Palomba M.L., Xu L, and Hunter ZR.

Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenström macroglobulinemia

Steven P. Treon, MD, PhD, Kirsten Meid, MPH, Christina Tripsas, MA, Leonard Heffner, MD, Herbert Eradat, MD, Ashraf Z. Badros, MD, Lian Xu, Zachary R. Hunter, PhD, Guang Yang, PhD, Christopher J. Patterson, MFA, Joshua Gustine, MPH, Jorge J. Castillo, MD, Jeffrey Matous, DM, and Irene M. Ghobrial, MD